Rhumbline Advisers Purchases 5,284 Shares of Haemonetics Corporation $HAE

Rhumbline Advisers lifted its holdings in Haemonetics Corporation (NYSE:HAE) by 3.3% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 166,407 shares of the medical instruments supplier’s stock after purchasing an additional 5,284 shares during the quarter. Rhumbline Advisers owned 0.35% of Haemonetics worth $12,416,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of HAE. Geode Capital Management LLC increased its stake in Haemonetics by 1.9% during the second quarter. Geode Capital Management LLC now owns 1,244,624 shares of the medical instruments supplier’s stock worth $92,873,000 after acquiring an additional 23,257 shares during the last quarter. Royal Bank of Canada boosted its holdings in shares of Haemonetics by 2.3% in the 1st quarter. Royal Bank of Canada now owns 1,075,604 shares of the medical instruments supplier’s stock worth $68,355,000 after purchasing an additional 24,650 shares during the period. SG Capital Management LLC increased its position in shares of Haemonetics by 92.5% during the 2nd quarter. SG Capital Management LLC now owns 906,892 shares of the medical instruments supplier’s stock valued at $67,663,000 after purchasing an additional 435,660 shares during the last quarter. Citigroup Inc. raised its holdings in Haemonetics by 87.3% during the 1st quarter. Citigroup Inc. now owns 625,565 shares of the medical instruments supplier’s stock valued at $39,755,000 after buying an additional 291,574 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its position in Haemonetics by 0.9% in the first quarter. Charles Schwab Investment Management Inc. now owns 556,027 shares of the medical instruments supplier’s stock worth $35,336,000 after buying an additional 4,834 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Haemonetics Stock Up 0.7%

Shares of Haemonetics stock opened at $81.35 on Monday. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.72 and a quick ratio of 1.04. The stock has a market cap of $3.81 billion, a price-to-earnings ratio of 24.88, a PEG ratio of 0.91 and a beta of 0.43. The firm’s 50-day moving average is $58.57 and its two-hundred day moving average is $63.31. Haemonetics Corporation has a 1 year low of $47.31 and a 1 year high of $88.86.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.12 by $0.15. The firm had revenue of $327.32 million for the quarter, compared to the consensus estimate of $311.61 million. Haemonetics had a net margin of 12.14% and a return on equity of 26.64%. The company’s quarterly revenue was down 5.3% on a year-over-year basis. During the same period last year, the firm earned $1.12 earnings per share. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. As a group, research analysts expect that Haemonetics Corporation will post 4.55 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on HAE shares. Needham & Company LLC lifted their price target on shares of Haemonetics from $68.00 to $78.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Raymond James Financial reaffirmed an “outperform” rating and set a $90.00 target price on shares of Haemonetics in a research note on Friday, November 14th. Barrington Research increased their price target on Haemonetics from $86.00 to $90.00 and gave the stock an “outperform” rating in a report on Friday, November 7th. Mizuho dropped their price objective on Haemonetics from $90.00 to $70.00 and set an “outperform” rating for the company in a report on Friday, August 8th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $88.00 price objective on shares of Haemonetics in a research report on Friday, November 21st. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Haemonetics currently has an average rating of “Moderate Buy” and an average price target of $79.70.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.